Enliven Therapeutics, Inc. (ELVN) has a consensus analyst rating of Buy, based on 6 analysts covering the stock. Of those, 6 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for ELVN is $43.33, representing a -3.4% downside from the current price of $44.85. Price targets range from a low of $39.00 to a high of $52.00.
